• On 27 June 2026, Nektar Therapeutics (NasdaqCM:NKTR) was added to a wide suite of Russell indexes, including the Russell 2000, 2500, 3000, and several associated growth and value benchmarks, expanding its presence across multiple small-cap and broad-market portfolios.
• This broad index inclusion simultaneously places Nektar in both value and growth benchmarks, highlighting how different investors and models may interpret its risk–reward profile in contrasting ways.
• Next, we will examine how Nektar’s broad Russell index inclusion, especially across both growth and value benchmarks, may influence its investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Nektar Therapeutics Investment Narrative Recap

To own Nektar today, you need to believe that REZPEG can eventually translate promising mid‑stage data and FDA Fast Track status into a viable commercial autoimmune franchise, despite ongoing losses and reliance on external funding. The broad Russell index additions may modestly support trading liquidity and visibility, but they do not materially change the near term dependence on REZPEG’s Phase 3 execution or the key risk of continued cash burn and potential future dilution.

Among recent developments, the April 2026 Phase 2b REZOLVE‑AD readout is most relevant here, because it underpins why index providers are now slotting Nektar into both growth and value baskets. Durable efficacy signals in atopic dermatitis, alongside plans to start the Phase 3 ZENITH‑AD program, keep clinical progress at the center of the story, while the new index exposure may broaden the shareholder base just as the program moves into a more capital intensive stage.

Yet in contrast to the Russell inclusion, investors should be aware that the risk of prolonged losses and further equity raises could still...

Nektar Therapeutics' narrative projects $54.9 million revenue and $10.7 million earnings by 2029. This requires fairly flat yearly revenue growth and a $168.8 million earnings increase from -$158.1 million today.

Uncover how Nektar Therapeutics' forecasts yield a $153.25 fair value, a 113% upside to its current price.

Exploring Other Perspectives

Before this index news, the most optimistic analysts projected revenue near US$136,000,000 by 2029, which contrasts sharply with concerns about persistent losses and limited partnerships that could constrain Nektar’s options if expectations for REZPEG or future M&A interest do not play out as hoped.

Explore 3 other fair value estimates on Nektar Therapeutics - why the stock might be worth just $153.25!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Nektar Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Nektar Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nektar Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 44 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.